New monthly shot cuts migraine days in half for chronic sufferers?
NCT ID NCT03867201
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tested whether a monthly injection of erenumab could reduce the number of migraine days in adults with chronic migraine (15 or more headache days per month). Over 550 Asian participants received either the drug or a placebo for 12 weeks. The main goal was to see how much migraine days dropped during the last 4 weeks of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Erenumab (a biologic drug given by injection once a month)
What this could lead to
If it works, this could provide a new monthly treatment option to reduce the number of migraine days for people with chronic migraine.
What could go wrong
This trial is completed and showed positive results, but it only lasted 12 weeks and focused on Asian populations, so long-term effects and benefits in other groups are not yet known.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Beijing, Beijing Municipality, 100000, China
-
Novartis Investigative Site
Beijing, Beijing Municipality, 100039, China
-
Novartis Investigative Site
Xiamen, Fujian, 361001, China
-
Novartis Investigative Site
Guangzhou, Guangdong, 510000, China
-
Novartis Investigative Site
Shijiazhuang, Hebei, 500051, China
-
Novartis Investigative Site
Zhengzhou, Henan, 450052, China
-
Novartis Investigative Site
Jingzhou, Hubei, 434020, China
-
Novartis Investigative Site
Wuhan, Hubei, 430060, China
-
Novartis Investigative Site
Changsha, Hunan, 410003, China
-
Novartis Investigative Site
Changsha, Hunan, 410008, China
-
Novartis Investigative Site
Nanjing, Jiangsu, 210008, China
-
Novartis Investigative Site
Nanjing, Jiangsu, 210029, China
-
Novartis Investigative Site
Suzhou, Jiangsu, 215004, China
-
Novartis Investigative Site
Wuxi, Jiangsu, 214002, China
-
Novartis Investigative Site
Changchun, Jilin, 130021, China
-
Novartis Investigative Site
Changchun, Jilin, 130041, China
-
Novartis Investigative Site
Shenyang, Liaoning, 100016, China
-
Novartis Investigative Site
Yinchuan, Ningxia, 100039, China
-
Novartis Investigative Site
Jinan, Shandong, 250013, China
-
Novartis Investigative Site
Xian, Shanxi, 710061, China
-
Novartis Investigative Site
Chengdu, Sichuan, 610041, China
-
Novartis Investigative Site
Kunming, Yunnan, 650000, China
-
Novartis Investigative Site
Hangzhou, Zhejiang, 310006, China
-
Novartis Investigative Site
Hangzhou, Zhejiang, 310016, China
-
Novartis Investigative Site
Beijing, 065001, China
-
Novartis Investigative Site
Beijing, 100050, China
-
Novartis Investigative Site
Chongqing, 400016, China
-
Novartis Investigative Site
Qingdao, 266000, China
-
Novartis Investigative Site
Shanghai, 200040, China
-
Novartis Investigative Site
Shanghai, 200080, China
-
Novartis Investigative Site
Nashik, Maharashtra, 422005, India
-
Novartis Investigative Site
Lucknow, Uttar Pradesh, 226014, India
-
Novartis Investigative Site
Dehradun, Uttarakhand, 248001, India
-
Novartis Investigative Site
Seberang Jaya, Pulau Pinang, 13700, Malaysia
-
Novartis Investigative Site
Sungai Buloh, Selangor, 47000, Malaysia
-
Novartis Investigative Site
Kuala Terengganu, Terengganu, 20400, Malaysia
-
Novartis Investigative Site
Kuala Lumpur, 59100, Malaysia
-
Novartis Investigative Site
Manila, National Capital Region, 1000, Philippines
-
Novartis Investigative Site
Pasig, 1605, Philippines
-
Novartis Investigative Site
Singapore, 169608, Singapore
-
Novartis Investigative Site
Hwaseong-si, Gyeonggi-do, 18450, South Korea
-
Novartis Investigative Site
Seoul, Korea, 08308, South Korea
-
Novartis Investigative Site
Gyeonggi-do, 11765, South Korea
-
Novartis Investigative Site
Seoul, 03080, South Korea
-
Novartis Investigative Site
Seoul, 03181, South Korea
-
Novartis Investigative Site
Seoul, 03722, South Korea
-
Novartis Investigative Site
Seoul, 139-711, South Korea
-
Novartis Investigative Site
Chiayi City, 60002, Taiwan
-
Novartis Investigative Site
Taichung, 40447, Taiwan
-
Novartis Investigative Site
Taichung County, 411743, Taiwan
-
Novartis Investigative Site
Tainan, 701, Taiwan
-
Novartis Investigative Site
Tainan, 71004, Taiwan
-
Novartis Investigative Site
Taipei, 10449, Taiwan
-
Novartis Investigative Site
Taipei, 11217, Taiwan
-
Novartis Investigative Site
Taipei, 114, Taiwan
-
Novartis Investigative Site
Taoyuan, 33305, Taiwan
-
Novartis Investigative Site
Bangkok, THA, 10400, Thailand
-
Novartis Investigative Site
Khon Kaen, THA, 40002, Thailand
-
Novartis Investigative Site
Bangkok, 10330, Thailand
-
Novartis Investigative Site
Bangkok, 10400, Thailand
-
Novartis Investigative Site
Chiang Mai, 50200, Thailand
-
Novartis Investigative Site
Ho Chi Minh City, VNM, 700000, Vietnam
-
Novartis Investigative Site
Hanoi, 100000, Vietnam